Deals channel feed

Ex­clu­sive: Al­pha­bet's Iso­mor­phic inks first phar­ma deals with Eli Lil­ly and No­var­tis for $83M up­front, $2.9B in mile­stones

Last year
Startups
AI

Cerev­el failed to draw Pfiz­er in­to a bid­ding war, but got Ab­b­Vie to up its price any­way, fil­ing shows

Last year

Mer­ck CEO in­di­cates in­ter­est in GLP-1 com­bi­na­tion ther­a­pies, may pur­sue deals

Last year
R&D

Ab­b­Vie taps Umo­ja for new in vi­vo CAR-T deal

Last year
Cell/Gene Tx

4BIO pulls De­vel­op­ment Bank of Japan to dip its toes in­to UK life sci­ence by back­ing lat­est fund

Last year
Financing
R&D

Roche pens third pact of the week in $66M up­front to MO­MA Ther­a­peu­tics

Last year
Startups
Pharma

Ex­clu­sive: Af­ter Turn­ing Point suc­cess, on­col­o­gy vets in-li­cense first as­set for Aven­zo Ther­a­peu­tics

Last year
Startups
China

No­vo’s broad Flag­ship part­ner­ship starts with obe­si­ty at Omega and MASH at Cel­lar­i­ty

Last year
Startups
Pharma

GSK shrinks Scynex­is deal af­ter de­lay in com­mer­cial­iza­tion of an­ti­fun­gal drug

Last year
Pharma
Manufacturing

Boehringer In­gel­heim once again turns to RNAi for new MASH ther­a­pies

Last year

Roche lines up RNA pact with Remix Ther­a­peu­tics, which al­so raised an­oth­er $60M

Last year
Financing
Startups

NGM Bio sub­ject of take-pri­vate bid by in­sti­tu­tion­al in­vestor The Col­umn Group

Last year
R&D

Roche inks $50M ADC pact with Chi­nese biotech as field­'s flur­ry spills over in­to 2024

Last year
China
Pharma

No­var­tis dou­bles down on neu­ro­log­ic gene ther­a­py work with Voy­ager

Last year
Pharma
Cell/Gene Tx

Im­mu­ni­ty­Bio inks roy­al­ty deal, pri­vate place­ment to raise $210M for blad­der can­cer drug com­bo

Last year
Financing

Ex­clu­sive: Weeks af­ter $213M launch, Tome ac­quires a Berke­ley gene edit­ing start­up for DNA lig­ase tech­nol­o­gy

Last year
Cell/Gene Tx

As­traZeneca makes $1B deal for Gra­cell and its cell ther­a­pies, adding to Chi­na ties

Last year
China
Cell/Gene Tx

J&J li­cens­es LegoChem's Trop2 ADC for $100M up­front

Last year

Bris­tol My­ers to buy Rayze­Bio for $4.1B as phar­ma piles in­to bur­geon­ing ra­dio­phar­ma field

Last year

Ab­b­Vie's $10B Im­muno­Gen deal was won by pay­ing $7 a share over a ri­val bid­der's of­fer, SEC fil­ings show

Last year

Bris­tol My­ers bets on neu­ro­science surge with $14B Karuna cash ac­qui­si­tion

Last year
Pharma

J&J buys eye dis­ease gene ther­a­py from MeiraGTx, giv­ing the biotech the cash in­fu­sion it was seek­ing

Last year
Cell/Gene Tx

Lil­ly part­ners with start­up Fau­na Bio to see if a squir­rel’s hi­ber­na­tion could lead to new obe­si­ty drugs

Last year
Startups
Pharma

Bris­tol My­ers gets reg­u­la­to­ry clear­ance to close Mi­rati deal as FTC in­creas­es pres­sure on phar­ma M&A

Last year
Pharma
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times